07.30.15
ICON plc has partnered with Mereo BioPharma Group, a specialty biopharma company, under which ICON will be the sole provider of clinical development services.
Mereo, based in the UK, is focused on acquiring, developing and commercializing innovative medicines to treat rare and specialized disease areas. The company’s initial portfolio consists of clinical-stage products acquired from Novartis to treat brittle bone syndrome, acute exacerbations of chronic obstructive pulmonary disease, and hypogonadotropic hypogonadism.
Ciaran Murray, chief executive officer of ICON said, “We are delighted to have been selected as Mereo’s clinical development partner. It is a further endorsement of ICON’s expertise in operating under partnership models, which leverage our deep industry expertise, operational excellence and differentiated technology solutions. We look forward to helping Mereo accelerate the development of their pipeline and bring to market drugs that will enhance the quality of patients’ lives.”
Mereo BioPharma’s chief executive officer, Dr. Denise Scots-Knight, said, “Our partnership with ICON provides us with a dedicated and experienced global team that is already working closely with Mereo. The relationship is designed not only to help us conduct global clinical studies as we develop our product portfolio, but also to leverage ICON’s broader consulting expertise. We look forward to a fruitful alliance, progressing our pipeline in the clinic and ultimately delivering new valuable medicines to patients.”
Mereo, based in the UK, is focused on acquiring, developing and commercializing innovative medicines to treat rare and specialized disease areas. The company’s initial portfolio consists of clinical-stage products acquired from Novartis to treat brittle bone syndrome, acute exacerbations of chronic obstructive pulmonary disease, and hypogonadotropic hypogonadism.
Ciaran Murray, chief executive officer of ICON said, “We are delighted to have been selected as Mereo’s clinical development partner. It is a further endorsement of ICON’s expertise in operating under partnership models, which leverage our deep industry expertise, operational excellence and differentiated technology solutions. We look forward to helping Mereo accelerate the development of their pipeline and bring to market drugs that will enhance the quality of patients’ lives.”
Mereo BioPharma’s chief executive officer, Dr. Denise Scots-Knight, said, “Our partnership with ICON provides us with a dedicated and experienced global team that is already working closely with Mereo. The relationship is designed not only to help us conduct global clinical studies as we develop our product portfolio, but also to leverage ICON’s broader consulting expertise. We look forward to a fruitful alliance, progressing our pipeline in the clinic and ultimately delivering new valuable medicines to patients.”